These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 25593071

  • 1. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
    Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, Xu H, Xing M, Qu S.
    Endocr Relat Cancer; 2015 Apr; 22(2):159-68. PubMed ID: 25593071
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C, Guo Y, Lv Y, Nanding A, Shi T, Qin H, He J.
    PLoS One; 2016 Apr; 11(12):e0167414. PubMed ID: 27936049
    [Abstract] [Full Text] [Related]

  • 3. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
    Park VY, Kim EK, Lee HS, Moon HJ, Yoon JH, Kwak JY.
    Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
    [Abstract] [Full Text] [Related]

  • 4. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.
    Ma YJ, Deng XL, Li HQ.
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):591-599. PubMed ID: 26223933
    [Abstract] [Full Text] [Related]

  • 5. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
    Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM.
    Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
    [Abstract] [Full Text] [Related]

  • 6. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
    Yang X, Liang ZY, Meng C, Liang J, Yu Z, Lin YS.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
    [Abstract] [Full Text] [Related]

  • 7. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK, Song KH, Lim SD, Lim YC, Yoo YB, Kim JS, Hwang TS.
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [Abstract] [Full Text] [Related]

  • 8. BRAF Status in Papillary Microcarcinomas of the Thyroid Gland: a Brief Review.
    Ieni A, Vita R, Cardia R, Giuffré G, Benvenga S, Tuccari G.
    Curr Mol Med; 2019 Feb; 19(9):665-672. PubMed ID: 31625469
    [Abstract] [Full Text] [Related]

  • 9. The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
    Shen G, Kou Y, Liu B, Huang R, Kuang A.
    Nucl Med Commun; 2019 Jan; 40(1):8-13. PubMed ID: 30312216
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma.
    Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR.
    Radiology; 2009 Dec; 253(3):854-60. PubMed ID: 19710001
    [Abstract] [Full Text] [Related]

  • 12. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.
    Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML.
    Mod Pathol; 2013 Jan; 26(1):62-70. PubMed ID: 22918165
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
    Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W.
    Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
    [Abstract] [Full Text] [Related]

  • 16. Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma.
    Zhou YL, Zhang W, Gao EL, Dai XX, Yang H, Zhang XH, Wang OC.
    Asian Pac J Cancer Prev; 2012 Feb; 13(4):1267-72. PubMed ID: 22799316
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Association of BRAFV600E mutation with ultrasonographic features and clinicopathologic characteristics of papillary thyroid microcarcinoma: A retrospective study of 116 cases.
    Chen B, Zhang Z, Wang K, Shang M, Zhao S, Ding W, Du R, Yu Z, Xu X.
    Clin Hemorheol Microcirc; 2019 Feb; 73(4):545-552. PubMed ID: 31306113
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer.
    Campennì A, Ruggeri RM, Giuffrè G, Siracusa M, Alibrandi A, Cardile D, La Torre F, Lanzafame H, Giacoppo G, Ieni A, Trimarchi F, Tuccari G, Baldari S.
    Nucl Med Commun; 2021 Jun 01; 42(6):611-618. PubMed ID: 33625185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.